Clemens Wendtner, Talha Munir, and Alessandra Tedeschi look back on the year so far in CLL, reviewing developments from clinical trials as well as real-world and comparative studies before considering how data drive individual treatment decisions.

Stephan Stilgenbauer, Meletios Dimopoulos, and Stefano Luminari look back on ASH, highlighting developments with BTK inhibitor-based therapies in CLL and immunotherapies in FL.

Christian Buske, Wojciech Jurczak and Rebecca Auer explore the current treatment landscape for R/R FL and consider how new targeted and cellular therapies may transform patient outcomes.

Carol Moreno and Pier Luigi Zinzani share their highlights from two of the biggest annual events in hematology, focusing on developments that will shape the future of clinical practice in CLL and indolent lymphomas.

Alessandra Tedeschi, Lucrecia Yáñez and Thorsten Zenz use interactive patient case studies to illustrate the role of prior treatment experience, genetic/cytogenetic changes, comorbidities, and patient preference in guiding treatment choices in R/R CLL.

Christian Buske, Paolo Ghia and Shirley D’Sa reflect on the data presented at ASH 2022 that are most relevant for clinical practice, highlighting developments in CAR-T, bispecific antibody, and BTK inhibitor therapies, and more.

Francesc Bosch, Stephan Stilgenbauer and Alessandra Tedeschi discuss the first-line treatment of patients with CLL, including the role of first-line chemotherapy and selecting continuous vs time-limited targeted therapy.

Christian Buske, Véronique Leblond, Wojciech Jurczak and Pier Luigi Zinzani cover the highlights in lymphoma management that were announced during ASCO and EHA 2022.

Paolo Ghia, Davide Rossi and Anna Schuh discuss diagnosis and prognosis in CLL, including a case study on the differential diagnosis of accelerated CLL and Richter’s syndrome and a debate on the clinical relevance of IGHV and TP53 as biomarkers.

Christian Buske, Paolo Ghia, Wojciech Jurczak and Véronique Leblond review the most exciting announcements from ASH 2021, covering key developments in a range of lymphomas and leukemias including MCL, DLBCL, and CLL.

Wojciech Jurczak, Federico Pea, Paolo Ghia and Alessandra Tedeschi review the role of BTK inhibition in the treatment of R/R B-cell malignancies, with a special focus on next-generation BTKis.

Christian Buske, Wojciech Jurczak and Meletios Dimopoulos cover the key challenges in managing B-cell malignancies during the COVID-19 pandemic, including new evidence-based insights and recommendations for treating aggressive and indolent lymphomas and managing COVID-19 vaccinations.

Alessandra Tedeschi, Roger Owen, Michael Lunn, Véronique Leblond and Joe-Elie Salem review multidisciplinary management of Waldenström’s macroglobulinemia, including provision of specialist care beyond hematology.

Christian Buske, Ramón García-Sanz, Véronique Leblond and Alessandra Tedeschi focus on treatment for patients with relapsed and refractory Waldenström’s macroglobulinemia, and look to the future of Waldenström’s macroglobulinemia treatment.

Véronique Leblond, Meletios Dimopoulos, Ramón García-Sanz and Wojciech Jurczak outline the topic of treatment initiation for Waldenström’s macroglobulinemia, exploring treatment options, monitoring, and unmet needs.

Christian Buske, Alessandra Tedeschi and Roger Owen chart the diagnostic journey in Waldenström’s macroglobulinemia, covering topics such as diagnostic criteria, techniques for testing, differential diagnoses, staging and the impact of specific disease-associated mutations.